[Report and Recommendations] “Post G7 Ise-Shima Summit: Reflecting upon Japan’s National Action Plan and Addressing Next Steps for Global Antimicrobial Resistance”Meeting Summary – “Seven Recommendations for Promoting Measures Against AMR”
date : 11/14/2017
Tags: AMR
- Reaffirm the importance of proper and rapid examinations and reporting of results as a measure against AMR, and further promote the adoption of technologies that are already approved for use.
- Government authorities must consider measures to promote microbial testing – considered to be one measure against AMR – such as support for the adoption of rapid medical technology, or valuations necessary for medical reimbursement.
- The government must consider concrete measures for infection control (hospital-acquired infections, community-acquired infections), and evaluate medical facilities on their performance on such measures.
- Speed up the approval of so far non-approved reagents and technological equipment that has already been shown effective against AMR.
2. Provide concrete incentives for R&D
- Recognize the difficulties companies face when trying to predict revenue or hedge investment risks related to AMR-related R&D.
- Develop basic incentive plans in addition to financial support, to create an environment that will facilitate investment into AMR-related R&D and the appropriate use of related drugs after they enter the market.
3. Promote both the cross-sectoral and international integration of examination data
- Promote the cross-sectoral and international integration of data collected during examinations.
- Based on the analysis of such data, raise awareness about proper diagnoses through such activities as the distribution of diagnosis protocols that include information on diagnostic guidelines for infectious diseases.
4. Seek concrete progress in areas of cooperation between academia, government, and industry
- Promote cooperation between academia, government, and industry in fields that are pillars of measures against AMR, such as the promotion of proper detection and diagnoses, surveillance, and R&D.
- Establish, within the area of academia, government, and industry cooperation, such mechanisms that go beyond agenda-setting to concretely address issues related to the harmonizing of regulatory mechanisms and sharing of standardized data.
- Base these efforts on dialogue to promote mutual understanding and trust building.
5. Proceed with the implementation of the Action Plan while taking special care not to bring too many restrictions to bear
- Further implement cross-sectoral and multidisciplinary action plans. In implementing such plans, care should be taken to not overly restrict the use of antimicrobials while pursuing plan objectives.
6. Japan must continue to assume global leadership
- At the same time as Japan works for academia, government, and industry cooperation between itself, the countries of Europe, and the United States, Japan should also display international leadership with regard to outstanding AMR issues in Asia.
7. Promote further awareness-raising activities
- Promote further awareness-raising activities targeting the media and general public to help patients understand the problem themselves and discourage them from seeking antimicrobials when they do not need them.
Kuniaki Miyake (Director, Tuberculosis and Infectious Diseases Control
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases/
Professor, Department of Microbiology and Infectious Diseases, Toho University)
Panel Discussion 1
“G7 Ise-Shima Summit’s Achievements and Further Role to Combat AMR”
The discussion in Session 1 reflected on the changes made during the past year following the G7 Ise-Shima summit both globally and locally. The Panel elaborated on the complicated issue of the new framework for public-private partnerships (PPP) needed for AMR R&D policies.
• Gary M. Cohen (Executive Vice President and President, Global Health and Development, Becton, Dickinson and Company)
• Jayasree K. Iyer (Executive Director, Access to Medicine Foundation)
• Paul Schaper (Executive Director, Global Public Policy, Merck & Co., Inc., Kenilworth, N.J., U.S.A.)
• Naoko Yamamoto (Senior Assistant Minister for Global Health, MHLW)
Mayuka Yamazaki (Project Assistant Professor, Global Health Policy, Faculty of Medicine, The University of Tokyo)
“Challenges and Next Agendas in Japan’s National Action Plan”
In this session, experts had a focused discussion on the remaining challenges and future agenda related to Japan’s National Action Plan, including incentives to foster antimicrobial development as well as possible frameworks for the government-industry-academia partnerships critical to that process.
• Norio Ohmagari (Vice Director, National Center for Global Health and Medicine / Director, Disease Control and Prevention Center(DCC) / Director, International Health Care Center at DCC)
• Takuko Sawada (Director of the Board, Senior Executive Officer, Senior Vice President, Corporate Strategy Division, Shionogi & Co., Ltd.)
• Kazuhiko Mori (Director, Evaluation and Licensing Division, MHLW)
• Katsunori Yanagihara (Professor, Department of Laboratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University)
Ryoji Noritake
President, Health and Global Policy Institute (HGPI)
Keizo Takemi (Member of the House of Councillors)
Top Research & Recommendations Posts
- [Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Announcement] HGPI Joins Global Climate and Health Alliance (March 23, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] “International comparison of dementia policies, research study on information dissemination.” (April 10, 2024)
Featured Posts
-
2024-04-22
[Registration Open] (Hybrid Format) Intractable Disease Day Symposium: Future Measures for Intractable Diseases from the Perspectives of Patients and Citizens (May, 23 2024)
-
2024-04-23
[Registration Open] The 125th HGPI Seminar: Progress and Prospects for Domestic Measures on Health Problems Caused by Alcohol (May 24 , 2024)
-
2024-04-26
[Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
-
2024-05-01
[Registration Open] The Global Health Education Program (G-HEP) 2024 (May 1, 2024)
-
2024-05-02
[Announcement] Recruitment of the Health Policy Academy the 13th Session